¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå : À¯Çüº°, Á¦Ç°º°, ¿ëµµº°, ÀûÀÀ Áúȯº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Global Electroretinogram Market, By Type, By Product, By Application, By Disease Indication, By End User, By Geography
»óǰÄÚµå : 1449568
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,385,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,933,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,191,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀåÀº 2024³â¿¡´Â 4,870¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2031³â¿¡´Â 9,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2031³âÀÇ CAGRÀº 9.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2023 2023/2024³â ½ÃÀå ±Ô¸ð 4,870¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031
¿¹Ãø ±â°£2023/2024-2030/2031 CAGR : 9.20% 2030/2031³âÀÇ ¿¹ÃøÄ¡ 9,010¸¸ ´Þ·¯
µµÇ¥ 1. ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
Global Electroretinogram Market-IMG1

¸Á¸·Àüµµ´Â ¸Á¸·ÀÇ °Ç°­ »óÅÂ¿Í ±â´ÉÀ» Æò°¡Çϱâ À§ÇÑ Áø´Ü¿ë ÀÇ·á °Ë»çÀÔ´Ï´Ù. ¸Á¸·ÀÌ ºû Àڱؿ¡ ¾î¶»°Ô ¹ÝÀÀÇÏ´ÂÁö¸¦ ±â·ÏÇÏ¿© ¸Á¸·ÀÇ Àü±âÀû Ȱµ¿À» °´°üÀûÀ¸·Î ÃøÁ¤ÇÕ´Ï´Ù. °Ë»ç¿¡¼­´Â ȯÀÚÀÇ ¾È±¸ Ç¥¸é°ú µÎÇÇ¿¡ Àü±ØÀ» ¼³Ä¡ÇÕ´Ï´Ù. ÀÌÈÄ ±¤¿øÀ¸·Î ¸Á¸·À» ºñÃ߸鼭 Àü±âÀû ¹ÝÀÀÀ» ±â·ÏÇÕ´Ï´Ù. ¸Á¸·ÀüÀ§µµ ¶Ç´Â ¸Á¸·ÀüÀ§µµ(ERG)´Â ¸Á¸·ÀÇ Áý´ÜÀû Àü±âÀû ¹ÝÀÀÀ» ÃøÁ¤ÇÏ¿© ¸Á¸·»ö¼Òº¯¼ºÁõ°ú °°Àº Áúȯ°ú °ü·ÃµÈ ¸Á¸·ÀÇ ÀÌ»óÀ» °¨ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Àü ¼¼°è¿¡¼­ ¸Á¸· ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾È°ú ÁúȯÀÇ Áø´Ü°ú °ü¸®¸¦ °³¼±Çϱâ À§ÇØ ERG¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¼¼°è ¸Á¸·ÀüÀ§µµ ½ÃÀåÀº ³ëÈ­·Î ÀÎÇÑ ¸Á¸· Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, ´ç´¢º´¼º ¸Á¸·Áõ ¹ßº´·ü Áõ°¡, ¾È°ú ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ´ÙÃÊÁ¡ ¸Á¸·ÀüÀ§µµ¸¦ ÅëÇÕÇÑ ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¸¹Àº ½ÅÈï ±¹°¡¿¡¼­´Â ¸Á¸·ÀüÀ§µµ ÀåºñÀÇ ³ôÀº ºñ¿ë°ú ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·À¸·Î ÀÎÇØ °³¹ßÀÌ ¾ïÁ¦µÉ ¼ö ÀÖ½À´Ï´Ù. ½ÅÈï ±¹°¡µéÀº ±Þ¼ÓÇÑ °æÁ¦ ¹ßÀü°ú ÀÇ·á ÀÎÇÁ¶ó È®ÃæÀ¸·Î ½ÃÀå °³Ã´Àڵ鿡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, POC(Point-of-Care) °Ë»ç¸¦ À§ÇÑ ÈÞ´ë¿ë ±â±âÀÇ ¿¬±¸°³¹ß(R&D)¿¡ ÅõÀÚÇÏ´Â Á¦Á¶¾÷üµé¿¡°Ôµµ ±âȸ°¡ È®´ëµÉ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ÃËÁø¿äÀÎÀº Ȳ¹Ýº¯¼º, ³ì³»Àå µî ³ëÈ­¿¡ µû¸¥ ¸Á¸· Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡ÀÔ´Ï´Ù. Àü ¼¼°è¿¡¼­ ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ÁúȯÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µÀ» À§ÇÑ ERG¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡ÇÒ °ÍÀÔ´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº ´ç´¢º´ÀÇ ÇÕº´ÁõÀÎ ´ç´¢º´¼º ¸Á¸·ÁõÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Àü ¼¼°è¿¡¼­ ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾È°ú °ü·Ã ÇÕº´ÁõÀÇ Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ERG ÀåºñÀÇ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´« °ü¸®¿Í Á¤±âÀûÀÎ ¾È°ú °ËÁøÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀåÀ» ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç ³ë·Â°ú ´« °Ç°­¿¡ ´ëÇÑ ±³À° Ä·ÆäÀÎÀº ´õ ¸¹Àº »ç¶÷µéÀÌ ERG °Ë»ç¸¦ Æ÷ÇÔÇÑ Á¾ÇÕÀûÀÎ ¾È°ú °ËÁøÀ» ¹Þµµ·Ï µ¶·ÁÇϰí ÀÖ½À´Ï´Ù. ´ÙÃÊÁ¡ ¸Á¸·Àü»êÈ­´ÜÃþÃÔ¿µ°ú °°Àº ±â¼ú ¹ßÀüÀ¸·Î ERG ÀåºñÀÇ Á¤È®µµ¿Í È¿À²¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´Ù¾çÇÑ ¸Á¸· ÁúȯÀÇ Áø´Ü°ú Ä¡·á¿¡ ERGÀÇ ¿ëµµ¸¦ È®´ëÇÏ¿© ¾È°ú Àǻ翡°Ô ±ÍÁßÇÑ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)°¡ 2022³â 10¿ù¿¡ Á¦°øÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2020³â¿¡´Â 60¼¼ ÀÌ»ó ³ëÀÎÀÇ ¼ö°¡ 5¼¼ ¹Ì¸¸ ¾î¸°À̺¸´Ù ¸¹À» °ÍÀ̸ç, 2015-2050³â ¼¼°è Àα¸¿¡¼­ 60¼¼ ÀÌ»óÀÌ Â÷ÁöÇÏ´Â ºñÁßÀº 12%¿¡¼­ 22%·Î °ÅÀÇ µÎ ¹è·Î Áõ°¡ÇÒ °ÍÀÔ´Ï´Ù. ÀÇ Àα¸ ºñÁßÀº 2020³â 100¸¸ ¸í¿¡¼­ 140¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ̸ç, 2050³â±îÁö Àü ¼¼°è 60¼¼ ÀÌ»ó Àα¸´Â µÎ ¹è(210¸¸ ¸í)·Î Áõ°¡ÇÒ °ÍÀ̸ç, 80¼¼ ÀÌ»ó ³ëÀÎÀÇ ¼ö´Â 2020³â¿¡¼­ 2050³â »çÀÌ¿¡ 3¹è·Î Áõ°¡ÇÏ¿© 4¾ï 2,600¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå, À¯Çüº°, 2019-2031³â

Á¦6Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå, Á¦Ç°º°, 2019-2031³â

Á¦7Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå, ¿ëµµº°, 2019-2031³â

Á¦8Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå, Áúȯ ÀûÀÀº°, 2019-2031³â

Á¦9Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°,2019-2031³â

Á¦10Àå ¼¼°èÀÇ ¸Á¸·Àüµµ ½ÃÀå, Áö¿ªº°, 2019-2031³â

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¼½¼Ç

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global electroretinogram market is valued at US$ 48.7 Mn in 2024 and is expected to reach US$ 90.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 48.7 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 9.20% 2030/2031 Value Projection: US$ 90.1 Mn
Figure 1. Global Electroretinogram Market Share (%), By Region, 2024
Global Electroretinogram Market - IMG1

Electroretinography is a diagnostic medical test that is used to evaluate the health and function of the retina. It provides objective measurements of the retina's electrical activity by recording how it responds to light stimulus. The test involves placing electrodes on the surface of the eye and the scalp of the patient. A light source is then used to illuminate the retina while recording any electrical responses. The electroretinogram or electroretinogram (ERG) measures the mass electric response of the retina and can help detect retinal abnormalities that are associated with diseases like retinitis pigmentosa. Rising prevalence of retinal disorders worldwide is anticipated to drive increased reliance on ERG for improved diagnosis and management of ocular conditions.

Market Dynamics:

Global electroretinogram market is driven by the growing geriatric population prone to age-related retinal diseases, rising incidence of diabetic retinopathy, growing awareness about eye care, and technological advancements incorporating and multifocal electroretinography. However, the market growth can be restrained by the high cost of electroretinogram devices and non-availability of skilled professionals in many developing regions. Emerging economies offer lucrative opportunities for market players as they witness rapid economic development and healthcare infrastructure expansion. Manufacturers investing in research and development (R&D) of portable devices for point-of-care (POC) testing can also open up opportunities.

A primary driver is the increasing geriatric population, which is more susceptible to age-related retinal diseases such as macular degeneration and glaucoma. As the number of elderly individuals rises globally, the demand for ERG for the diagnosis and monitoring of these conditions also increases. Another significant factor is the rising incidence of diabetic retinopathy, a complication of diabetes that affects the eyes. Growing prevalence of diabetes worldwide has led to an increase in demand for early detection and treatment of eye-related complications, thereby propelling the use of ERG devices. Heightened awareness about eye care and the importance of regular eye examinations has further stimulated the market. Public health initiatives and educational campaigns about eye health have encouraged more people to seek comprehensive eye examinations, which often include ERG testing. Technological advancements, such as the incorporation of multifocal electroretinography, have improved the accuracy and efficiency of ERG devices. These innovations have expanded the applications of ERG in diagnosing and treating a variety of retinal conditions, thus making it a valuable tool for ophthalmologists.

For instance, in October 2022, according to data provided by the World Health Organization (WHO), in 2020, the number of people aged 60 years and older outnumbered children younger than 5 years. Between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. The share of the population aged 60 years and over will increase from 1 million in 2020 to 1.4 million. By 2050, the world's population of people aged 60 years and olders will double (2.1 million). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Electroretinogram Market- Impact of Coronavirus (COVID-19) Pandemic

5. Global Electroretinogram Market, By Type, 2019-2031, (US$ Mn)

6. Global Electroretinogram Market, By Product, 2019-2031, (US$ Mn)

7. Global Electroretinogram Market, By Application, 2019-2031, (US$ Mn)

8. Global Electroretinogram Market, By Disease Indication, 2019-2031, (US$ Mn)

9. Global Electroretinogram Market, By End User, 2019-2031, (US$ Mn)

10. Global Electroretinogram Market, By Region, 2019-2031, (US$ Mn)

11. Competitive Landscape

12. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â